Richard Hafner

8.1k total citations · 2 hit papers
86 papers, 5.2k citations indexed

About

Richard Hafner is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Richard Hafner has authored 86 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Infectious Diseases, 66 papers in Epidemiology and 16 papers in Virology. Recurrent topics in Richard Hafner's work include Tuberculosis Research and Epidemiology (38 papers), Pneumocystis jirovecii pneumonia detection and treatment (36 papers) and HIV/AIDS drug development and treatment (25 papers). Richard Hafner is often cited by papers focused on Tuberculosis Research and Epidemiology (38 papers), Pneumocystis jirovecii pneumonia detection and treatment (36 papers) and HIV/AIDS drug development and treatment (25 papers). Richard Hafner collaborates with scholars based in United States, France and United Kingdom. Richard Hafner's co-authors include Alimuddin Zumla, Mario Raviǵlione, C. Fordham von Reyn, Robert S. Wallis, William G. Powderly, Wafaa El‐Sadr, Benjamin J. Luft, John P. Matts, Michael S. Saag and Gretchen A. Cloud and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Richard Hafner

84 papers receiving 5.0k citations

Hit Papers

Tuberculosis 1992 2026 2003 2014 2013 1992 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tuberculosis
    2013 529 citations Alimuddin Zumla, Mario Raviǵlione et al. New England Journal of Medicine profile →
  2. Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis
    1992 470 citations William G. Powderly, Gretchen A. Cloud et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Hafner United States 40 3.7k 3.4k 722 547 491 86 5.2k
Antonio Rivero Spain 40 3.3k 0.9× 2.6k 0.8× 385 0.5× 192 0.4× 270 0.5× 307 6.3k
Gretchen A. Cloud United States 50 5.7k 1.6× 5.1k 1.5× 278 0.4× 294 0.5× 628 1.3× 95 8.4k
Srikanth Tripathy India 36 1.5k 0.4× 2.6k 0.8× 600 0.8× 203 0.4× 440 0.9× 236 4.2k
Jonathan Gold United States 37 2.9k 0.8× 2.3k 0.7× 315 0.4× 563 1.0× 365 0.7× 80 5.6k
Marco Schito United States 33 1.7k 0.5× 2.1k 0.6× 633 0.9× 453 0.8× 833 1.7× 73 4.7k
Monto Ho United States 42 3.2k 0.9× 2.3k 0.7× 607 0.8× 204 0.4× 761 1.5× 114 6.6k
Giampiero Carosi Italy 38 7.4k 2.0× 3.1k 0.9× 409 0.6× 133 0.2× 408 0.8× 164 10.7k
Esteban Ribera Spain 40 2.3k 0.6× 3.0k 0.9× 627 0.9× 181 0.3× 291 0.6× 231 5.5k
John M. Leedom United States 29 3.0k 0.8× 3.9k 1.2× 342 0.5× 286 0.5× 575 1.2× 75 6.3k
Sharon Safrin United States 33 2.6k 0.7× 1.6k 0.5× 225 0.3× 221 0.4× 223 0.5× 65 4.8k

Countries citing papers authored by Richard Hafner

Since Specialization
Citations

This map shows the geographic impact of Richard Hafner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Hafner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Hafner more than expected).

Fields of papers citing papers by Richard Hafner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Hafner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Hafner. The network helps show where Richard Hafner may publish in the future.

Co-authorship network of co-authors of Richard Hafner

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Hafner. A scholar is included among the top collaborators of Richard Hafner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Hafner. Richard Hafner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chirehwa, Maxwell, Elisa H. Ignatius, Richard Court, et al.. (2022). Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. 77(9). 2489–2499. 7 indexed citations
2.
Dorhoi, Anca, Leigh A. Kotzé, Jay A. Berzofsky, et al.. (2020). Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus. Journal of Clinical Investigation. 130(6). 2789–2799. 34 indexed citations
3.
Liu, Yuhong, Shu Chen, Jingtao Gao, et al.. (2020). The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building. Infectious Diseases of Poverty. 9(1). 52–52.
4.
Gordhan, Bhavna G., Elizabeth M. Streicher, Gavin Churchyard, et al.. (2016). Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 194(12). 1532–1540. 93 indexed citations
5.
Zumla, Alimuddin, et al.. (2013). CURRENT CONCEPTS Tuberculosis. UCL Discovery (University College London). 3 indexed citations
6.
Nahid, Payam, Jussi Saukkonen, William R. Mac Kenzie, et al.. (2011). Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap. American Journal of Respiratory and Critical Care Medicine. 184(8). 972–979. 41 indexed citations
7.
Tebas, Pablo, Richard Hafner, Karen T. Tashima, et al.. (2009). Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110. Journal of Antimicrobial Chemotherapy. 63(5). 998–1005. 23 indexed citations
8.
Glesby, Marshall J., Judith A. Aberg, Michelle A. Kendall, et al.. (2005). Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clinical Pharmacology & Therapeutics. 78(2). 143–153. 69 indexed citations
9.
MacGregor, Rob Roy, Richard Hafner, Julia Wu, et al.. (2005). Clinical, Microbiological, and Immunological Characteristics in HIV-Infected Subjects at Risk for Disseminated Mycobacterium avium Complex Disease: An AACTG Study. AIDS Research and Human Retroviruses. 21(8). 689–695. 8 indexed citations
10.
Aberg, Judith A., Paige L. Williams, Tun Liu, et al.. (2003). A Study of Discontinuing Maintenance Therapy in Human Immunodeficiency Virus–Infected Subjects with DisseminatedMycobacterium aviumComplex: AIDS Clinical Trial Group 393 Study Team. The Journal of Infectious Diseases. 187(7). 1046–1052. 27 indexed citations
11.
Chirgwin, Keith, Richard Hafner, Catherine Leport, et al.. (2002). Randomized Phase II Trial of Atovaquone with Pyrimethamine or Sulfadiazine for Treatment of Toxoplasmic Encephalitis in Patients with Acquired Immunodeficiency Syndrome: ACTG 237/ANRS 039 Study. Clinical Infectious Diseases. 34(9). 1243–1250. 68 indexed citations
12.
Jacobson, Jeffrey M., Richard Hafner, Jack S. Remington, et al.. (2001). Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 15(5). 583–589. 30 indexed citations
13.
Wheat, L. Joseph, Gretchen A. Cloud, Philip C. Johnson, et al.. (2001). Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus Itraconazole. Antimicrobial Agents and Chemotherapy. 45(8). 2354–2357. 63 indexed citations
14.
Benson, Constance A., Paige L. Williams, David L. Cohn, et al.. (2000). Clarithromycin or Rifabutin Alone or in Combination for Primary Prophylaxis ofMycobacterium aviumComplex Disease in Patients with AIDS: A Randomized, Double‐Blind, Placebo‐Controlled Trial. The Journal of Infectious Diseases. 181(4). 1289–1297. 62 indexed citations
15.
El‐Sadr, Wafaa, William J. Burman, John P. Matts, et al.. (2000). Discontinuation of Prophylaxis againstMycobacterium aviumComplex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine. 342(15). 1085–1092. 101 indexed citations
16.
Cohn, David L., Evelyn J. Fisher, James S. Hodges, et al.. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients. 67. 1 indexed citations
17.
Cohn, David L., Evelyn J. Fisher, James S. Hodges, et al.. (1999). A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: Excess mortality associated with high-dose clarithromycin. 67. 520–521. 1 indexed citations
18.
19.
Hafner, Richard, David J. Wright, Nancy E. Dunlap, et al.. (1997). Early Bactericidal Activity of Isoniazid in Pulmonary Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 156(3). 918–923. 34 indexed citations
20.
Luft, Benjamin J., Richard Hafner, Ann H. Korzun, et al.. (1993). Toxoplasmic Encephalitis in Patients with the Acquired Immunodeficiency Syndrome. New England Journal of Medicine. 329(14). 995–1000. 293 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Rivero Breakdown of academic impact, for papers by Gretchen A. Cloud Breakdown of academic impact, for papers by Srikanth Tripathy Breakdown of academic impact, for papers by Jonathan Gold Breakdown of academic impact, for papers by Marco Schito Breakdown of academic impact, for papers by Monto Ho Breakdown of academic impact, for papers by Giampiero Carosi Breakdown of academic impact, for papers by Esteban Ribera Breakdown of academic impact, for papers by John M. Leedom Breakdown of academic impact, for papers by Sharon Safrin
Rankless by CCL
2026